Celularity (CELU) Total Current Liabilities (2018 - 2025)
Celularity (CELU) posted quarterly Total Current Liabilities of $80.8 million for Q4 2025, up 50.45% year-over-year from $53.7 million in Q4 2024, and up 23.65% quarter-over-quarter from $65.3 million in Q3 2025.
Celularity (CELU) Total Current Liabilities (2018 - 2025) Analysis & Trends
Celularity (CELU) has reported Total Current Liabilities for 8 consecutive years, with $80.8 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Total Current Liabilities rose 50.45% year-over-year to $80.8 million; the TTM figure through Dec 2025 stood at $80.8 million (up 50.45% YoY), while the FY2025 annual figure was $80.8 million, up 50.45% from the prior year.
- Total Current Liabilities rose to $80.8 million in Q4 2025 per CELU's latest filing, from $65.3 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $84.6 million in Q3 2023 and bottomed at $5.2 million in Q1 2021.
- Historically, Total Current Liabilities has averaged $54.0 million across 5 years, with a median of $65.1 million in 2023.
- Annual changes were most pronounced in 2021 — Total Current Liabilities soared 20571.7% — and 2024, when it slipped 20.24%.
- Celularity's Total Current Liabilities stood at $26.2 million in 2021, then jumped by 136.75% to $62.1 million in 2022, then rose by 8.39% to $67.3 million in 2023, then retreated by 20.24% to $53.7 million in 2024, then soared by 50.45% to $80.8 million in 2025.
- Business Quant data shows CELU's Total Current Liabilities at $80.8 million in Q4 2025, $65.3 million in Q3 2025, and $69.2 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.57 Bn | 130.72 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 85.99 Bn | 77.99 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 65.00 Bn | 59.82 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 56.27 Bn | 51.13 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 42.00 Bn | 36.90 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 31.60 Bn | 28.29 Bn | 992.69 Mn | 1.51 Bn |
| 7 | BioNTech SE | 27.68 Bn | 9.29 Bn | 668.28 Mn | 2.49 Bn |
| 8 | Insmed | 27.43 Bn | 26.27 Bn | 358.27 Mn | 438.74 Mn |
| 9 | Royalty Pharma | 27.34 Bn | 26.51 Bn | - | 630.93 Mn |
| 10 | Celularity | 19.68 Mn | 13.50 Mn | -3.27 Mn | 80.76 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 80.76 Mn |
| Sep 30, 2025 | 65.31 Mn |
| Jun 30, 2025 | 69.23 Mn |
| Mar 31, 2025 | 58.69 Mn |
| Dec 31, 2024 | 53.68 Mn |
| Sep 30, 2024 | 76.17 Mn |
| Jun 30, 2024 | 67.90 Mn |
| Mar 31, 2024 | 66.04 Mn |
| Dec 31, 2023 | 67.30 Mn |
| Sep 30, 2023 | 84.63 Mn |
| Jun 30, 2023 | 64.98 Mn |
| Mar 31, 2023 | 66.46 Mn |
| Dec 31, 2022 | 62.09 Mn |
| Sep 30, 2022 | 69.22 Mn |
| Jun 30, 2022 | 32.94 Mn |
| Mar 31, 2022 | 26.03 Mn |
| Dec 31, 2021 | 26.23 Mn |
| Sep 30, 2021 | 29.21 Mn |
| Jun 30, 2021 | 7.29 Mn |
| Mar 31, 2021 | 5.16 Mn |